Theralink Technologies Stock Price, News & Analysis

THER OTC

Company Description

Theralink Technologies, Inc. (symbol: THER) is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer immunotherapy products. With a focus on prostate and breast cancers, the company leverages its proprietary immunotherapy platform to pioneer new treatments in the oncology sector.

Theralink's lead product, ProscaVax, is currently in phase 2 clinical trials for the treatment of prostate cancer, showcasing promising potential in its early stages. In addition to ProscaVax, the company is actively developing targeted therapies to enhance their oncology portfolio.

In partnership with Perthera, Inc., Theralink aims to facilitate and enhance access to its proprietary 32 phosphoprotein panel, known as the Theralink Assay, specifically for breast cancer patients. This partnership is a strategic move to expand their impact and reach within the cancer treatment landscape.

Established in Baton Rouge, Louisiana, Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. before rebranding in September 2020 to better reflect its innovative approach and expanded focus.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

- %

Performance 1 year

$615.1K

Market Cap

6.2B

Shares outstanding

Latest News

View All

December 18, 2023

14.29%

Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates

November 13, 2023

18.18%

Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4

November 3, 2023

20.00%

Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board

October 4, 2023

11.11%

Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023

acquisition earnings

June 27, 2023

8.00%

Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer

management

April 3, 2023

4.35%

Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University

acquisition

SEC Filings

View All

No SEC filings available for Theralink Technologies.

Financial Highlights

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Theralink Technologies (THER)?

The current stock price of Theralink Technologies (THER) is $0.0001 as of April 24, 2025.

What is the market cap of Theralink Technologies (THER)?

The market cap of Theralink Technologies (THER) is approximately 615.1K.

What does Theralink Technologies, Inc. specialize in?

Theralink Technologies, Inc. specializes in developing cancer immunotherapy products, focusing primarily on prostate and breast cancers.

What is ProscaVax?

ProscaVax is Theralink Technologies, Inc.'s lead product, currently in phase 2 clinical trials for the treatment of prostate cancer.

Which types of cancer does Theralink focus on?

Theralink focuses on prostate and breast cancers.

What is the Theralink Assay?

The Theralink Assay is a proprietary 32 phosphoprotein panel developed to facilitate targeted cancer therapies, especially for breast cancer patients.

Who is Theralink's partner?

Theralink has a partnership with Perthera, Inc. to enhance access to the Theralink Assay for breast cancer patients.

Where is Theralink Technologies, Inc. located?

Theralink Technologies, Inc. is based in Baton Rouge, Louisiana.

What was Theralink Technologies, Inc. formerly known as?

The company was formerly known as OncBioMune Pharmaceuticals, Inc. before changing its name to Theralink Technologies, Inc. in September 2020.

What stage are the clinical trials for ProscaVax in?

ProscaVax is in phase 2 clinical trials.

Does Theralink Technologies develop other therapies?

Yes, Theralink Technologies is also developing targeted therapies in addition to their immunotherapy products.

How does Theralink aim to impact cancer treatment?

Theralink aims to impact cancer treatment through innovative immunotherapy products and strategic partnerships to enhance access to targeted therapies.